

2020 SABCS Disclosures

Program #	Talk Title	First Name	Last Name	Degrees	Disclosure Information
Executive/Program Planning Committee Member		Carlos L.	Arteaga	MD	Dr. Arteaga has disclosed consulting fees from Novartis, Lilly, Merck, Sanofi, Daiichi Sankyo, PUMA Biotechnology, RADIUS, TAIHO Oncology, Petra Pharma, Immunomedics, G1 Therapeutics, Athenex, Abbvie, H3Biomedicine, Origimed, and Clovis. He has also disclosed ownership interest with Provista and Y-TRAP and contracted research receiving research grants from Pfizer, Lilly, TAKEDA and Bayer. He has also disclosed ownership interest in Provista, and Y-Trap. He is on the scientific advisory board Komen Foundation. These financial relationships will not impact his ability to present an unbiased presentation.
Program Planning Committee Member		Aditya	Bardia	MBBS (MD), MPH	Dr. Bardia has disclosed consulting fees from Novartis, Pfizer, Daiichi/Astra-Zeneca, Sanofi, Genentech/Roche, Radius Health, Merck, Eli Lilly, PUMA and Immunomedics. He has also disclosed contracted research from Institution Funding (as PI): Novartis, Pfizer, Sanofi, Genentech/Roche, Radius Health, Merck and Immunomedics. Dr. Bardia intends to reference unlabeled/unapproved uses of drugs or products in his presentation.
Staff		Susan	Binger		Ms. Binger has no relevant financial relationships with commercial interests to disclose.
Program Planning Committee Member		Leticia Z.	Bresnahan		Ms. Bresnahan has no relevant financial relationships with commercial interests to disclose.
Executive/Program Planning Committee Member		Gary	Chamness	PhD	Dr. Chamness has no relevant financial relationships with commercial interests to disclose.
Program Planning Committee Member		Chonghui	Cheng	MD, PhD	Dr. Cheng has no relevant financial relationships with commercial interests to disclose.
Program Planning Committee Member		Bonner M.	Cutting	BFA	Ms. Cutting has no relevant financial relationships with commercial interests to disclose.
Program Planning Committee Member		Rebecca	Dent	MD, MSc	Dr. Dent has disclosed consulting fees from Astra Zeneca, Eisai, Lilly, Merck, Novartis, Pfizer and Roche. She has also disclosed other conference travel, Astra Zeneca,, Merck, Pfizer and Roche. These financial relationships will not impact her ability to present an unbiased presentation.
Executive/Program Planning Committee Member		Margaret	Foti	PhD, MD (hc)	Dr. Foti has no relevant financial relationships with commercial interests to disclose.
Program Planning Committee Member		Suzanne	Fuqua	PhD	Dr. Fuqua has no relevant financial relationships with commercial interests to disclose.
Program Planning Committee Member		Judy E.	Garber	MD, MPH	Dr. Garber has disclosed consulting fees from Helix Genetics and contracted research from Amby Genetics and Myriad Genetics. She has also disclosed other consultant, no funds for Konica Minolta. These financial relationships will not impact her ability to present an unbiased presentation.
Program Planning Committee Member		William	Gradishar	MD	Dr. Gradishar has disclosed consulting fees with AstraZeneca, Lilly, Pfizer, MacroGenics, Genomic Health and Puma.
Staff		Sharon	Hill		Ms. Hill has no relevant financial relationships with commercial interests to disclose.
Program Planning Committee Member		Reshma	Jagsi	MD, Dphil	Reshma Jagsi has stock option as compensation for her advisory board role in Equity Quotient, a company that evaluates culture in health care companies; she has received personal fees from Amgen and Vizient and grants for unrelated work from the National Institutes of Health, the Doris Duke Foundation, the Greenwall Foundation, the Komen Foundation, and Blue Cross Blue Shield of Michigan for the Michigan Radiation Oncology Quality Consortium.
Program Planning Committee Member		Ismail	Jatoi	MD, PhD	Dr. Jatoi has no relevant financial relationships with commercial interests to disclose. Dr. Jatoi intends to reference unlabeled/unapproved uses of drugs or products in his presentation.
Program Planning Committee Member		Virginia	Kaklamani	MD, DSc	Dr. Kaklamani has disclosed consulting fees with Amgen, Eisai, Puma, Celldex, AstraZeneca and Athenex. She has also disclosed fees for non-cme services received directly from commercial interest or their agents from Pfizer, Celgene, Genentech, Genomic Health, Puma, Eisai and Novartis. Dr. Kaklamani has also disclosed contracted research with Eisai.
Program Planning Committee Member		Kate	Lathrop	MD	Dr. Lathrop has no relevant financial relationships with commercial interests to disclose.
Program Planning Committee Member		M. Kathryn	Leonard	PhD	Ms. Leonard has no relevant financial relationships with commercial interests to disclose.
Program Planning Committee Member		Eleftherios P.	Mamounas	MD, MPH	Dr. Mamounas has disclosed consulting fees from Roche/Genentech, Genomic Health, Inc, Daiichi Sankyo and Biotheranostics. He has also disclosed fees for non-cme services received directly from commercial interest or their agents with Roche/Genentech and Genomic Health, Inc.

2020 SABCS Disclosures

Executive/Program Planning Committee Member		Ruben	Mesa	MD	Dr. Mesa has disclosed consulting fees with Novartis, Sierra Onc, LaJolla and Pharma. He has also disclosed other Research Support: Celgene, Incyte, Abbvie, Samus, Genotech, Promedior and CTI. These financial relationships will not impact his ability to present an unbiased presentation.
Program Planning Committee Member		Elizabeth	Mittendorf	MD, PhD	Dr. Mittendorf has disclosed consulting fees from Merck, and Genomic Health and contracted research with Glaxo Smith Kline. These financial relationships will not impact her ability to present and unbiased presentation.
Program Planning Committee Member		Julie	Nangia	MD	Dr. Nangia has disclosed consulting fees with Novartis Consultancy. These financial relationships will not impact her ability to present an unbiased presentation.
Executive/Program Planning Committee Member		C. Kent	Osborne	MD	Dr. Osborne has disclosed consulting fees with AstraZeneca, Lilly, Genetech and Tolmar. These financial relationships will not impact his ability to present an unbiased presentation. Dr. Osborne has no relevant financial relationships with commercial interests to disclose.
Program Planning Committee Member		Charles K.	Perou	PhD	Dr. Perou has disclosed receipt of intellectual property rights/patent holder and ownership interest in Bioclassifier LLC, and GeneCentric Therapeutics. He has also disclosed royalties from Bioclassifier LLC and consulting fees from G1 Therapeutics, Ionis Pharmaceuticals, Nanostring Technologies, Biclassifier LLC, and GeneCentric Therapeutics. These financial relationships will not impact his ability to present and unbiased presentation.
Executive/Program Planning Committee Member		Dean	Post	BS	Mr. Post has no relevant financial relationships with commercial interests to disclose.
Program Planning Committee Member		Susan	Rafte		Ms. Rafte has no relevant financial relationships with commercial interests to disclose.
Program Planning Committee Member		Manjeet	Rao	PhD, MSc, BSc	Dr. Rao has no relevant financial relationships with commercial interests to disclose.
Program Planning Committee Member		Andrea L.	Richardson	MD, PhD	Dr. Richardson has disclosed receipt of intellectual property rights / patent holder with Myriad Genetics. These financial relationships will not impact her ability to present and unbiased presentation.
Program Planning Committee Member		Mothaffar F.	Rimawi	MD	Dr. Rimawi has disclosed consulting fees with Genentech, Macrogenics and Seattle Genetics. He has also disclosed contracted research with Pfizer and GSK. These financial relationships will not impact his ability to present an unbiased presentation.
Program Planning Committee Member		Rachel	Schiff	PhD	Dr. Schiff has disclosed royalty with Wolters Kluwer/ UpToDate and consulting fees from MacroGenomics. She has also disclosed contracted research with PUMA, Gilead and AstraZeneca. These financial relationships will not impact her ability to present an unbiased presentation.
Executive/Program Planning Committee Member		Stephanie	Shelton		Ms. Shelton has no relevant financial relationships with commercial interests to disclose.
Program Planning Committee Member		Kalliopi P.	Siziopikou	MD, PhD	Dr. Siziopikou has no relevant financial relationships with commercial interests to disclose.
Program Planning Committee Member		Alastair M.	Thompson	BSc (HONS), MB ChB, MD, FRCSEd	Dr. Thompson has no relevant financial relationships with commercial interests to disclose. Dr. Thompson intends to reference unlabeled/unapproved uses of drugs or products in his presentation.
Program Planning Committee Member		Eric P.	Winer	MD	Dr. Winer has disclosed consulting fees with Carrick, Genentech/Roche, GSK, Jounce, Leap, Lilly, Merck and Seattle Genetics. He has also disclosed contracted research with Genetech/Roche and Merck. These financial relationships will not impact his ability to present an unbiased presentation.
Program Planning Committee Member		Victor (Trey)	Ximenez		Mr. Ximenez has no relevant financial relationships with commercial interests to disclose.
Program Planning Committee Member		Douglas	Yee	MD	Dr. Yee has disclosed consulting fees from Puma Oncology and Martell Diagnostics. He has also disclosed contracted research with coordinating investigator for Boehringer Ingelheim phase 1B study of xentuzamab. Dr. Yee has disclosed ownership interest with Apogen Biotechnologies stock, no product and no stock value. He has also disclosed other Leadership Role in I-SPY 2 trial, Faculty and Committee for PER Int Breast Congress. These financial relationships will not impact his ability to present an unbiased presentation.
Program Planning Committee Member		Xiang	Zhang	PhD	Dr. Zhang has no relevant financial relationships with commercial interests to disclose.